Clinical Trials Logo

Colonic Neoplasms clinical trials

View clinical trials related to Colonic Neoplasms.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT05433402 Withdrawn - Clinical trials for Colon Cancer Stage III

Repurposing the Antipsychotic Drug Chlorpromazine as Adjuvant Therapeutic Agent for Resected Stage III Colon Cancer

Start date: July 20, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

chlorpromazine displays a series of remarkable bio-molecular effects in cancer cells, as inhibition of cell growth, nuclear aberrations, inhibition of the phosphoinositide 3-kinase/mammilian target of rapamycin (PI3K/mTOR) axis, induction of cytotoxic autophagy, inhibition of glutamate and DRD2 receptors. This study will evaluate the addition of chlorpromazine to the first-line therapeutic protocol in colon cancer stage III.

NCT ID: NCT05310565 Withdrawn - Clinical trials for Colon Cancer Stage III

The Effects of Chiropractic in Adults With Colon Cancer

CCX
Start date: January 1, 2025
Phase: N/A
Study type: Interventional

The main objectives of this single-arm pilot trial are to investigate the feasibility of our protocol in terms of 1) recruitment, 2) adherence, 3) tolerability, 4) acceptability and 5) retention. We aim to recruit 20 participants with advanced colon cancer (stage 3-4) who will have assessments of their autonomic nervous system function, carcinoembryonic antigen (CEA) levels, and patient-reported outcomes. Thereafter, patients will be directed to a nearby field clinic to receive twice-weekly cervical assessments & high-velocity, low-amplitude (HVLA) cervical adjustments for a period of 6 weeks. Re-assessments will be performed following 2 weeks and 6 weeks of chiropractic care.

NCT ID: NCT05178576 Withdrawn - Colon Cancer Clinical Trials

A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy

Start date: June 24, 2022
Phase: Phase 2
Study type: Interventional

This study will look at the recurrence-free survival of microsatellite-stable (MSS) colon cancer in patients are ctDNA (circulating tumor DNA) positive and treated with gevokizumab.

NCT ID: NCT05156463 Withdrawn - Breast Cancer Clinical Trials

The PAI Trial for Breast and Colon Cancer Survivors

Start date: April 12, 2022
Phase: N/A
Study type: Interventional

The purpose of the study is to determine if a Physical Activity Index (PAI) tool that collects measures on physical activity, strength training and sedentary behavior can be used in a clinical setting to monitor patient behavior and provide specific recommendations on how to achieve and maintain behavior goals. The tool will be used after treatment is completed in breast and colon cancer survivors and will test if physician counseling combined with patient self-monitoring improves physical activity and reduces sedentary behavior over time.

NCT ID: NCT04811833 Withdrawn - Clinical trials for Gastrointestinal Stromal Tumors

Gastrointestinal Anastomosis Using MonoPlus® Suture

GASTROMO
Start date: July 2022
Phase:
Study type: Observational

The primary aim of this study is to collect clinical data on the performance of MonoPlus® suture applied in routine clinical practice. Diverse parameters are to be used to assess the safety and efficacy of MonoPlus® suture for gastrointestinal anastomosis construction. This study has been designed to implement an action within the framework of a proactive Post Market Clinical Follow up (PMCF) activity.

NCT ID: NCT04518449 Withdrawn - Colon Cancer Clinical Trials

Medial Border of Laparoscopic D3 Lymphadenectomy for Right Colon Cancer

Start date: December 1, 2022
Phase:
Study type: Observational

This study investigats the gastrointestinal functional outcomes of laparoscopic D3 lymphadenectomy for right colon cancer with the medial border along the left side of superior mesenteric artery (SMA) versus the left side of superior mesenteric vein (SMV). This is a single center, prospective cohort study with a sample size of 264 patients. The primary endpoint is the incidence of diarrhea (evaluated using the Diarrhea Assessment Scale) one month after surgery.

NCT ID: NCT04274790 Withdrawn - Cancer of Colon Clinical Trials

Impact of 5-Fluorouracil (5-FU) on Cancer Cells From Liver Metastases of Colon Cancer

FLUORIB
Start date: June 1, 2021
Phase:
Study type: Observational

Analyze the dynamics of incorporation of 5-fluorouracil into cancer cell ribosomes from liver metastases of patient with metastatic colon cancer.

NCT ID: NCT03974984 Withdrawn - Surgery Clinical Trials

Anesthesia and Immunological and Oxidative Stress in Relation to Abdominal Cancer Surgery

ANIMOX
Start date: June 4, 2020
Phase:
Study type: Observational

Colorectal cancer is a frequent type of cancer accounting for 600,000 deaths annually. Surgical resection remains the best treatment for long-term survival. However, studies suggest that events in the perioperative period can induce metastasis formation and tumor growth. Tumor cells are released into the blood stream during surgery and the surgical stress may create a favorable environment for dissemination of tumor cells into distant tissue. This is done by a cascade of pro-cancerous catecholamines, prostaglandins and cytokines combined with an impaired anti-cancerous cell mediated immune response. Until recently, focus on the anesthetic management of cancer patients has been limited. Relatively small alterations in the perioperative anesthetic management may play a tremendous role in tumor progression. Optimizing anesthesia to reduce the surgical stress response could improve recurrence rates and long-term outcomes for cancer patients by inhibiting perioperative metastasis formation. Regional anesthesia and amide local anesthetics are suspected to calm the immunologic storm of prostaglandins, catecholamines and cytokines when used in the perioperative phase. Furthermore, volatile inhalational anesthesia is thought to modulate the immune system in a pro-cancerous way, while propofol may have opposite effects. Many of these recent studies are statistically underpowered and susceptible to bias, and experts in cancer treatment and anesthesia have emphasized the need for further research within this specific field. In this study the investigators aim to characterize differences in the immunologic response to surgery between inhalational, total intravenous and epidural anesthesia. This will be done by analyzing blood samples obtained in the perioperative period in patients undergoing different modes of anesthesia. The Investigators will furthermore describe the quality of recovery for patients anesthetized with the different methods

NCT ID: NCT03946033 Withdrawn - Colonic Neoplasms Clinical Trials

Impact of Immunoscore Colon Test on Adjuvant Therapeutic Strategy in Non-Metastatic Colon Cancer

PROSCORE
Start date: May 2019
Phase: N/A
Study type: Interventional

Immunoscore Colon Test (ICT) will be applied on tumor samples from curative surgery. In the Multidisciplinary Meeting (MM) evaluating the participant adjuvant strategy, a first decision will be taken, based on the participant medical record only. ICT will then be disclosed and the MM will take a second decision. The aim of the study is to observe if the ICT result modifies the treatment decision.

NCT ID: NCT03717038 Withdrawn - Clinical trials for Metastatic Colorectal Cancer

Sym004 Versus TAS-102 in Patients With mCRC

Start date: February 2019
Phase: Phase 3
Study type: Interventional

This is a Phase 3, randomized, open-label, 2-arm trial designed to evaluate overall survival (OS) following treatment with Sym004, an investigational medicinal product (IMP), versus TAS-102 (trifluridine/tipiracil), a comparator (control) agent.